Equity Profile

ORKA

Oruka Therapeutics, Inc.

Health CareBiotechnology$5.1B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to address unmet medical needs....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ORKA Q2-2026 Earnings Preview

Context

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to address unmet medical needs. Operating in the health care sector, Oruka is positioned to impact patient care through its research and development efforts in biotechnology.

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.82%

Avg Stock Reaction

-2.31%

Last Quarter Recap

In Q1-2026, Oruka reported an EPS of -$0.48, which was better than analyst expectations of -$0.52, resulting in an 8.4% surprise. However, the stock declined by 2.27% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are cautious as there are no analyst estimates available, leaving investors uncertain about performance metrics. The company has consistently beaten EPS estimates in the past, but revenue figures remain undisclosed.

Bull Case

If Oruka continues its trend of beating EPS estimates, it could signal strong operational efficiency and investor confidence, potentially driving the stock higher.

Bear Case

On the other hand, if the company fails to provide clear revenue guidance or shows continued losses, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue figures can Oruka provide for this quarter?

Clear revenue guidance will be critical for assessing the company's growth trajectory and investor confidence.

Will Oruka maintain its trend of beating EPS estimates?

Continuing to beat EPS estimates could bolster investor sentiment and support the stock price.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Oruka's potential for revenue growth based on its recent operational efficiencies, which could lead to better-than-expected results this quarter.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating operational strength.

Options pricing suggests a significant move, reflecting trader expectations of volatility that may not align with consensus views.

Key Risk

If revenue figures exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will determine if Oruka can sustain its momentum in beating EPS estimates while addressing revenue concerns.

Bull Confirmed If

A significant reduction in EPS losses, ideally moving closer to breakeven, would confirm the bull case.

Bear Confirmed If

If EPS worsens beyond -$0.50, it would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±35.62%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move of over 35%, indicating that traders expect high volatility around the earnings report.

Options are pricing ±35.6% while ORKA has averaged ±2.5% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

67.3%

Calls (600)P/C Ratio: 0.13Puts (6K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.7%, with a raw directional average of +2.7% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Oruka beats expectations and raises guidance, history suggests a potential average one-day move of +2.31%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see muted movement as investors digest the information.

Miss

If the company misses expectations, history suggests a potential average one-day move of -2.27%, leading to negative sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or clinical trial results.
2Management's commentary on cost management strategies.
3Insights into market demand for Oruka's therapies.
4Any potential partnerships or collaborations that could enhance growth.
5Guidance on future revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to address unmet medical needs....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ORKA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.82%

Avg Stock Reaction

-2.31%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Oruka continues its trend of beating EPS estimates, it could signal strong operational efficiency and investor confidence, potentially driving the stock higher.

Bear Case

On the other hand, if the company fails to provide clear revenue guidance or shows continued losses, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue figures can Oruka provide for this quarter?

Clear revenue guidance will be critical for assessing the company's growth trajectory and investor confidence.

Will Oruka maintain its trend of beating EPS estimates?

Continuing to beat EPS estimates could bolster investor sentiment and support the stock price.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Oruka's potential for revenue growth based on its recent operational efficiencies, which could lead to better-than-expected results this quarter.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating operational strength.

Options pricing suggests a significant move, reflecting trader expectations of volatility that may not align with consensus views.

Key Risk

If revenue figures exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will determine if Oruka can sustain its momentum in beating EPS estimates while addressing revenue concerns.

Bull Confirmed If

A significant reduction in EPS losses, ideally moving closer to breakeven, would confirm the bull case.

Bear Confirmed If

If EPS worsens beyond -$0.50, it would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±35.62%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move of over 35%, indicating that traders expect high volatility around the earnings report.

Options are pricing ±35.6% while ORKA has averaged ±2.5% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

67.3%

Calls (600)P/C Ratio: 0.13Puts (6K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Oruka beats expectations and raises guidance, history suggests a potential average one-day move of +2.31%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see muted movement as investors digest the information.

Miss

If the company misses expectations, history suggests a potential average one-day move of -2.27%, leading to negative sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or clinical trial results.
2Management's commentary on cost management strategies.
3Insights into market demand for Oruka's therapies.
4Any potential partnerships or collaborations that could enhance growth.
5Guidance on future revenue expectations.